Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $55.00 Consensus PT from Analysts

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $55.00.

SLN has been the topic of several analyst reports. Cantor Fitzgerald initiated coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, June 17th.

Silence Therapeutics Stock Up 4.5%

SLN stock opened at $10.92 on Friday. Silence Therapeutics has a fifty-two week low of $4.19 and a fifty-two week high of $11.06. The firm’s 50-day simple moving average is $7.82 and its 200 day simple moving average is $6.56. The stock has a market cap of $515.86 million, a PE ratio of -6.87 and a beta of 1.38.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). The firm had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.25 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. Equities analysts forecast that Silence Therapeutics will post -0.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors have recently bought and sold shares of SLN. Seven Fleet Capital Management LP acquired a new position in shares of Silence Therapeutics during the 4th quarter valued at $897,000. Ishara Investments LP acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at $1,459,000. Cantor Fitzgerald L. P. lifted its holdings in shares of Silence Therapeutics by 1.6% in the third quarter. Cantor Fitzgerald L. P. now owns 801,306 shares of the company’s stock valued at $4,159,000 after buying an additional 12,267 shares during the period. Bank of Montreal Can lifted its holdings in shares of Silence Therapeutics by 4.4% in the fourth quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock valued at $976,000 after buying an additional 6,692 shares during the period. Finally, Marshall Wace LLP boosted its stake in Silence Therapeutics by 87.1% during the fourth quarter. Marshall Wace LLP now owns 155,680 shares of the company’s stock valued at $947,000 after buying an additional 72,461 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.